Sangoi et al. compared the sensitivity of GATA-3 to mammaglobin and GCDFP-15 (BRST-2), and found that GATA-3 showed superior sensitivity in both metastatic carcinoma and matched primary tumor. Here, GATA3 is linked to metastatic carcinoma.